BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Zeng L, Cao J, Zhang X. Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract. World J Gastroenterol 2005; 11(39): 6202-6207 [PMID: 16273651 DOI: 10.3748/wjg.v11.i39.6202]
URL: https://www.wjgnet.com/1007-9327/full/v11/i39/6202.htm
Number Citing Articles
1
Fausto A. Varela, Thomas E. Hyland, Karin List. Extracellular Targeting of Cell Signaling in Cancer2018; : 91 doi: 10.1002/9781119300229.ch4
2
Fang Ye, Shuang Chen, Xingxing Liu, Xiaohong Ye, Keqi Wang, Zhiping Zeng, Ying Su, Xiao‐kun Zhang, Hu Zhou. 3‐Cl‐AHPC inhibits pro‐HGF maturation by inducing matriptase/HAI‐1 complex formationJournal of Cellular and Molecular Medicine 2019; 23(1): 155 doi: 10.1111/jcmm.13900
3
Christian Parr, Wen G. Jiang. Metastasis of Breast CancerCancer Metastasis – Biology and Treatment 2007; 11: 171 doi: 10.1007/978-1-4020-5867-7_9
4
Class 3 Hydrolases2009; : 367 doi: 10.1007/978-3-540-85703-7_49
5
QIAOLI ZHENG, HAIJIAN WU, JIANG CAO, JINGJIA YE. Hepatocyte growth factor activator inhibitor type-1 in cancer: Advances and perspectives (Review)Molecular Medicine Reports 2014; 10(6): 2779 doi: 10.3892/mmr.2014.2628
6
Xiaoxiao Du, Lingyan Wu, Muhammad Saif Ur Rahman, Xiaodong Teng, Lisong Teng, Jingjia Ye, Jiang Cao. Promoter Hypomethylation Is Responsible for Upregulated Expression of HAI-1 in Hepatocellular CarcinomaDisease Markers 2019; 2019: 1 doi: 10.1155/2019/9175215
7
Jingjia Ye, Makiko Kawaguchi, Yukihiro Haruyama, Ai Kanemaru, Tsuyoshi Fukushima, Koji Yamamoto, Chen‐Yong Lin, Hiroaki Kataoka. Loss of hepatocyte growth factor activator inhibitor type 1 participates in metastatic spreading of human pancreatic cancer cells in a mouse orthotopic transplantation modelCancer Science 2014; 105(1): 44 doi: 10.1111/cas.12306
8
Makiko Kawaguchi, Hiroaki Kataoka. Mechanisms of Hepatocyte Growth Factor Activation in Cancer TissuesCancers 2014; 6(4): 1890 doi: 10.3390/cancers6041890
9
Andrew S. Murray, Fausto A. Varela, Karin List. Type II transmembrane serine proteases as potential targets for cancer therapyBiological Chemistry 2016; 397(9): 815 doi: 10.1515/hsz-2016-0131
10
Benjamin Owusu, Robert Galemmo, James Janetka, Lidija Klampfer. Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor MicroenvironmentCancers 2017; 9(4): 35 doi: 10.3390/cancers9040035
11
Benjamin Y. Owusu, Shantasia Thomas, Phanindra Venukadasula, Zhenfu Han, James W. Janetka, Robert A. Galemmo, Lidija Klampfer. Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activationOncotarget 2017; 8(38): 63014 doi: 10.18632/oncotarget.18260
12
Kuniyo Inouye, Satoshi Tsuzuki, Makoto Yasumoto, Kenji Kojima, Seiya Mochida, Tohru Fushiki. Identification of the Matriptase Second CUB Domain as the Secondary Site for Interaction with Hepatocyte Growth Factor Activator Inhibitor Type-1*Journal of Biological Chemistry 2010; 285(43): 33394 doi: 10.1074/jbc.M110.115816
13
K. Ji, B.F. Sloane. Encyclopedia of Cell Biology2016; : 753 doi: 10.1016/B978-0-12-394447-4.10085-9
14
Hongmok Kwon, Hyunsoo Ha, Hayoung Jeon, Jaebong Jang, Sang-Hyun Son, Kiho Lee, Song-Kyu Park, Youngjoo Byun. Structure-activity relationship studies of dipeptide-based hepsin inhibitors with Arg bioisosteresBioorganic Chemistry 2021; 107: 104521 doi: 10.1016/j.bioorg.2020.104521
15
Ping Hu, Le Shang, Jincan Chen, Xuzheng Chen, Chun Chen, Wanjin Hong, Mingdong Huang, Peng Xu, Zhuo Chen. A nanometer-sized protease inhibitor for precise cancer diagnosis and treatmentJournal of Materials Chemistry B 2020; 8(3): 504 doi: 10.1039/C9TB02081K
16
Lotte K Vogel, Mona Sæbø, Camilla F Skjelbred, Kathrine Abell, Esben DK Pedersen, Ulla Vogel, Elin H Kure. The ratio of Matriptase/HAI-1mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individualsBMC Cancer 2006; 6(1) doi: 10.1186/1471-2407-6-176
17
Keiichiro Nakamura, Atsushi Hongo, Junichi Kodama, Yuji Hiramatsu. The role of hepatocyte growth factor activator inhibitor (HAI)‐1 and HAI‐2 in endometrial cancerInternational Journal of Cancer 2011; 128(11): 2613 doi: 10.1002/ijc.25606
18
Mei Ji, Shunshuang Li, Ya Xie, Zhao Zhao, Weizhong Chang, Yue Li, Xinghan Cheng, Zhuo Wang. Expression and prognostic value of matriptase in ovarian serous adenocarcinomaOncology Letters 2017; 13(3): 1741 doi: 10.3892/ol.2017.5600
19
Sauryang Kim, Jae Woong Yang, Chungho Kim, Moon Gyo Kim. Impact of suppression of tumorigenicity 14 (ST14)/serine protease 14 (Prss14) expression analysis on the prognosis and management of estrogen receptor negative breast cancerOncotarget 2016; 7(23): 34643 doi: 10.18632/oncotarget.9155
20
Carolyn V. Ustach, Wei Huang, M. Katie Conley-LaComb, Chen-Yong Lin, Mingxin Che, Judith Abrams, Hyeong-Reh Choi Kim. A Novel Signaling Axis of Matriptase/PDGF-D/β-PDGFR in Human Prostate CancerCancer Research 2010; 70(23): 9631 doi: 10.1158/0008-5472.CAN-10-0511
21
Karin List, Thomas H. Bugge, Roman Szabo. Matriptase: Potent Proteolysis on the Cell SurfaceMolecular Medicine 2006; 12(1-3): 1 doi: 10.2119/2006-00022.List
22
Lidija Klampfer, Benjamin Yaw Owusu. Extracellular Targeting of Cell Signaling in Cancer2018; : 45 doi: 10.1002/9781119300229.ch2
23
Topi A. Tervonen, Johanna I. Partanen, Sirkku T. Saarikoski, Mikko Myllynen, Elsa Marques, Katriina Paasonen, Anu Moilanen, Gerd Wohlfahrt, Panu E. Kovanen, Juha Klefstrom. Advances in Cancer Research 2011; 111: 97 doi: 10.1016/B978-0-12-385524-4.00003-9
24
K U Sales, S Friis, L Abusleme, N M Moutsopoulos, T H Bugge. Matriptase promotes inflammatory cell accumulation and progression of established epidermal tumorsOncogene 2015; 34(35): 4664 doi: 10.1038/onc.2014.391
25
Benjamin Y. Owusu, Namita Bansal, Phanindra K.M. Venukadasula, Larry J. Ross, Troy E. Messick, Sanjay Goel, Robert A. Galemmo, Lidija Klampfer. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signalingOncotarget 2016; 7(20): 29492 doi: 10.18632/oncotarget.8785
26
Lauren M. Tanabe, Karin List. The role of type II transmembrane serine protease‐mediated signaling in cancerThe FEBS Journal 2017; 284(10): 1421 doi: 10.1111/febs.13971
27
Tao Ning, Haiyang Zhang, Xinyi Wang, Shuang Li, Le Zhang, Ting Deng, Likun Zhou, Xia Wang, Rui Liu, Ming Bai, Shaohua Ge, Hongli Li, Dingzhi Huang, Guoguang Ying, Yi Ba. miR-221 and miR-222 synergistically regulate hepatocyte growth factor activator inhibitor type 1 to promote cell proliferation and migration in gastric cancerTumor Biology 2017; 39(6): 101042831770163 doi: 10.1177/1010428317701636
28
Toni M. Antalis, Thomas H. Bugge, Qingyu Wu. Proteases in Health and DiseaseProgress in Molecular Biology and Translational Science 2011; 99: 1 doi: 10.1016/B978-0-12-385504-6.00001-4
29
Newton J. Hurst, Abdo J. Najy, Carolyn V. Ustach, Lisa Movilla, Hyeong-Reh Choi Kim. Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progressionBiochemical Journal 2012; 441(3): 909 doi: 10.1042/BJ20111020
30
Phanindra K. M. Venukadasula, Benjamin Y. Owusu, Namita Bansal, Larry J. Ross, Judith V. Hobrath, Donghui Bao, Jackie W. Truss, Murray Stackhouse, Troy E. Messick, Lidija Klampfer, Robert A. Galemmo. Design and Synthesis of Nonpeptide Inhibitors of Hepatocyte Growth Factor ActivationACS Medicinal Chemistry Letters 2016; 7(2): 177 doi: 10.1021/acsmedchemlett.5b00357
31
Joanna Selzer-Plon, Jette Bornholdt, Stine Friis, Hanne C Bisgaard, Inger MB Lothe, Kjell M Tveit, Elin H Kure, Ulla Vogel, Lotte K Vogel. Expression of prostasin and its inhibitors during colorectal cancer carcinogenesisBMC Cancer 2009; 9(1) doi: 10.1186/1471-2407-9-201
32
Sander P.J. Joosten, Marcel Spaargaren, Hans Clevers, Steven T. Pals. Hepatocyte growth factor/MET and CD44 in colorectal cancer: partners in tumorigenesis and therapy resistanceBiochimica et Biophysica Acta (BBA) - Reviews on Cancer 2020; 1874(2): 188437 doi: 10.1016/j.bbcan.2020.188437
33
Tsuyoshi Fukushima, Makiko Kawaguchi, Masatoshi Yamasaki, Hiroyuki Tanaka, Kenji Yorita, Hiroaki Kataoka. Hepatocyte growth factor activator inhibitor type 1 suppresses metastatic pulmonary colonization of pancreatic carcinoma cellsCancer Science 2011; 102(2): 407 doi: 10.1111/j.1349-7006.2010.01808.x
34
Aaron C. Mitchell, Deepti Kannan, Sean A. Hunter, R. Andres Parra Sperberg, Cheryl H. Chang, Jennifer R. Cochran. Engineering a potent inhibitor of matriptase from the natural hepatocyte growth factor activator inhibitor type-1 (HAI-1) proteinJournal of Biological Chemistry 2018; 293(14): 4969 doi: 10.1074/jbc.M117.815142
35
Vishnu C Damalanka, James W Janetka. Recent Progress on Inhibitors of the Type II Transmembrane Serine proteases, hepsin, Matriptase and matriptase-2Future Medicinal Chemistry 2019; 11(7): 743 doi: 10.4155/fmc-2018-0446
36
Kuniyo Inouye, Makoto Yasumoto, Satoshi Tsuzuki, Seiya Mochida, Tohru Fushiki. The optimal activity of a pseudozymogen form of recombinant matriptase under the mildly acidic pH and low ionic strength conditionsThe Journal of Biochemistry 2010; 147(4): 485 doi: 10.1093/jb/mvp190
37
Kyungmin Ji, Bonnie F. Sloane. Encyclopedia of Cell Biology2023; : 712 doi: 10.1016/B978-0-12-821618-7.00236-4